ArticleFrontiers in immunology2018
Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Quantitative Proteomic Analysis of Macrophages Infected withInternational journal of molecular sciences · 2024Article
- Antimicrobial activity of NK cells to Trypanosoma cruzi infected human primary Keratinocytes.PLoS neglected tropical diseases · 2024Article
- Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction.Current heart failure reports · 2024Review
- Platelets, Macrophages, and Thromboinflammation in Chagas Disease.Journal of inflammation research · 2022Review
- Different Transcriptomic Response toFrontiers in cellular and infection microbiology · 2022Article
- C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome ofFrontiers in immunology · 2022Article
- Role of the PD-1/PD-L1 Pathway in ExperimentalFrontiers in immunology · 2022Article
- Article
- Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.Herz · 2020Review
- The Role of PD-1 in Acute and Chronic Infection.Frontiers in immunology · 2020Review
- Immunity and vaccine development efforts against Trypanosoma cruzi.Acta tropica · 2019Review
- An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain ofFrontiers in immunology · 2019Article
- PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is a neglected parasitic infection that affects around six to seven million people, mainly in Latin America. About 30-35% of infected people present chronic Chagas cardiomyopathy (CCC), which eventually leads to death. This condition is characterized by local parasite persistence and leukocyte infiltration. In a murine model of CCC, we observed that among infiltrating leukocytes, CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.